Inve India ▾
PFPFIZER

Pfizer Q2 FY17 results (Jul–Sep 2016) and concall

Healthcare · Concall AI · Call held 7 Nov 2016

Company page: Pfizer share price, financials & guidance record

Source transcript

Pfizer India delivered a resilient quarter despite significant regulatory headwinds, including unanticipated price controls under Para 18 which impacted margins. The company is actively rationalizing its portfolio, evidenced by the ₹110 crore divestment of tail brands to Piramal. Management is transitioning to a new customer-centric 'route-to-market' structure and preparing for a major SAP rollout in 2017.

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.